Abstract
Therapy-related MDS and AML are complications of intensive chemotherapy regimens. Traditionally, patients exposed to topoisomerase II inhibitors are reported to develop secondary AML with abnormalities of chromosome 11q23. We evaluated the long-term hematologic toxicity of topoisomerase II-intensive high-dose mitoxantrone-based chemotherapy in 163 newly diagnosed acute leukemia patients treated over an 8 year period. Nine (5.5%) patients developed new cytogenetic abnormalities. Four patients developed MDS with progression to AML, three patients developed new abnormalities at the time of relapse, and three patients (including one of the former patients) had changes that were not associated with hematologic disease. The abnormalities most frequently involved chromosomes 7q, 20q, 1q, and 13q. Despite the use of topoisomerase II-intensive treatment, no patient developed an abnormality involving chromosome 11q23. Spontaneous resolution of some changes and prolonged persistence of others in the absence of hematologic disease indicates that some cytogenetic changes are not sufficient to promote leukemogenesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Mayer RJ, Davis RB, Schiffer CA, Berk DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E, for the Cancer and Leukemia Group B . Intensive postremission chemotherapy in adults with acute myeloid leukemia N Engl J Med 1994 331: 896–903
Bishop JS, Matthews JP, Young GA, Bradstock K, Lowenthal RM . Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group Leuk Lymphoma 1998 28: 315–327
Burnett AK, Goldstone AH, Stevens RM, Hann IM, Rees JK, Gray RG, Wheatley K . Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukemia in first remission: results of MRC AML 10 trial Lancet 1998 351: 700–708
Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G . Autologous or allogeneic bone marrow transplantation compared to intensive chemotherapy in acute myelogenous leukemia N Engl J Med 1995 332: 217–223
Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P . Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia Blood 1995 86: 3542–3552
Thirman MJ, Gill HJ, Burnett RC, Mbangkollo D, McCabe NR, Kobayashi H, Ziemin van der Poel S, Kaneko Y, Morgan R, Sandberg AA, Chaganti RSK, Larson RA, Le Beau MM, Diaz MO, Rowley JD . Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations N Engl J Med 1993 329: 909–914
Gill Super HJ, McCabe NR, Thirman MJ, Larson RA, Le Beau MM, Pedersen-Bjergaard J, Philip P, Diaz MO, Rowley JD . Rearrangements of the MLL gene in therapy-related acute myelogenous leukemia in patients previously treated with agents targeting DNA-topoisomerase II Blood 1993 82: 3705–3711
Raynaud SD, Brunet B, Chischportich M, Bayle J, Gratecos N, Pesce A, Dujardin P, Flandrin G, Ayraud N . Recurrent cytogenetic abnormalities observed in complete remission of acute myeloid leukemia do not necessarily mark preleukemic cells Leukemia 1994 8: 245–249
Imrie KR, Dube I, Prince HM, Girouard C, Crump M, Keating A . New clonal karyotypic abnormalities acquired following autologous bone marrow transplantation for acute myeloid leukemia do not appear to confer an adverse prognosis Bone Marrow Transplant 1998 21: 395–399
Detourmignies L, Castaigne S, Stoppa AM, Harousseau JL, Sadoun A, Janvier M, Demory JL, Sanz M, Berger R, Bauters F . Therapy-related acute promyelocytic leukemia: a report on 16 cases J Clin Oncol 1992 10: 1430–1435
Quesnel B, Kantarjian H, Pedersen-Bjergaard J, Brault P, Estey E, Lai JL, Tilly H, Stoppa AM, Archimbaud E, Harousseau JL, Bauters F, Fenaux P . Therapy-related acute myeloid leukemia with t(8;21), inv 16, and t(8;16). A report on 25 cases and review of the literature J Clin Oncol 1993 11: 2370–2379
Pedersen-Bjergaard J, Brondum-Nielsen K, Karle H, Johansson B . Chemotherapy-related and late occurring Philadelphia chromosome in AML, ALL and CML Similar events related to treatment with DNA topoisomerase II inhibitors? Leukemia 1997 11: 1571–1574
Lambertenghi Deliliers G, Annaloro C, Pozzoli E, Oriani A, Volpe AD, Soligo D, Lambertenghi Deliliers D, Tagliaferri E, Bertolli V, Romitti L . Cytogenetic and myelodysplastic alterations after autologous hemopoietic stem cell transplantation Leukemia Res 1999 23: 291–297
Chu JY, Batanian JR, Gale GB, Dunphy CH, DeMello DE . Spontaneous resolution of myelodysplastic cytogenetic abnormality developed during the treatment of leukemia J Pediatr Hematol Oncol 1998 20: 88–90
Alberts DS, Young L, Mason N, Salmon SE . In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by peritoneal administration Semin Oncol 1985 12 (Suppl. 4): 38–42
Feldman EJ, Seiter K, Traganos F, Darzynkiewicz Z, Goff H, Pozzuoli M, Baskind P, Santos S, Ahmed T . Phase II evaluation of a high-dose mitoxantrone based induction regimen in untreated adults with acute myeloid leukemia Leuk Lymphoma 2000 8: 309–315
Arlin ZA, Feldman EJ, Finger LR, Ahmed T, Mittelman A, Cook P, Puccio C, Baskind P, Arnold P, Razis ED . Short course high-dose mitoxantrone with high-dose cytarabine is effective therapy for adult lymphoblastic leukemia Leukemia 1991 5: 712–714
Weiss MA, Drullinsky P, Maslak P, Scheinberg D, Golde DW . A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia Leukemia 1998 12: 865–868
Feldman EJ, Seiter K, Damon L, Linker C, Rugo H, Ries C, Case DC JR, Beer M, Ahmed T . A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia Leukemia 1997 11: 485–489
Seiter K, Feldman EJ, Halicka HD, Deptala A, Traganos F, Burke HB, Hoang A, Goff H, Pozzuoli M, Kancherla R, Darzynkiewicz Z, Ahmed T . Clinical and laboratory evaluation of all-trans retinoic acid modulation of chemotherapy in patients with acute myelogenous leukemia Br J Haematol 2000 108: 40–47
Weiss M, Maslak P, Feldman E, Berman E, Bertino J, Gee T, Megherian L, Seiter K, Scheinberg D, Golde D . Cytarabine with high-dose mitoxantrone induces rapid complete remission in adult acute lymphoblastic leukemia without the use of vincristine or prednisone J Clin Oncol 1996 14: 2480–2485
Yunis JJ . High resolution of human chromosomes Science 1976 191: 1268–1270
Seabright M . A rapid banding technique for human chromosomes Lancet 1971 2: 971–972
ISCN . Mitelman F (ed). An International System for Human Cytogenetic Nomenclature S Karger: Basel 1995
Papageorgio C, Seiter K, Feldman EJ . Therapy-related myelodysplastic syndrome in adults with neurofibromatosis Leuk Lymphoma 1999 32: 605–608
Le Beau MW, Espinosa III R, Davis EM, Eisenbart JD, Larson RA, Green ED . Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases Blood 1996 88: 1930–1935
Fischer K, Frohling S, Scherer SW, McAllister Brown J, Scholl C, Stilgenbauer S, Tsui L-C, Lichter P, Dohner H . Molecular cytogenetic delineation of deletions and translocations involving chromosome band 7q22 in myeloid leukemias Blood 1997 89: 2036–2041
Liang H, Fairman J, Claxton DF, Nowell PC, Green ED, Nagarajan L . Molecular anatomy of chromosome 7q deletions in myeloid malignancies: evidence for multiple critical loci Proc Natl Acad Sci USA 1998 31: 3781–3785
Mahgoub N, Taylor BR, Le Beau MM, Gratiot M, Carlson KM, Atwater SK, Jacks T, Shannon KM . Myeloid malignancies induced by alkylating agents in Nf1 mice Blood 1999 93: 3617–3623
Kurtin PJ, Dewald GW, Shields DJ, Hanson CA . Hematologic disorders associated with deletions of chromosome 20q Am J Clin Pathol 1996 106: 680–688
Campbell LJ, Garson OM . The prognostic significance of deletion of the long arm of chromosome 20 in myeloid disorders Leukemia 1994 8: 67–71
Wattel E, Lai JL, Preudhomme C, Grahek D, Morel P, Bauters F, Fenaux P . De novo myelodysplastic syndrome (MDS) with deletion of the long arm of chromosome 20: a subtype of MDS with distinct hematologic and prognostic features? Leuk Res 1993 17: 921–926
Mogul MJ, Brady K, Brothman AR, Adams R, Peterson FB . Beatty PG. Myelodysplastic syndrome presenting with clonal rearrangement isolated to chromosomal region 1q Cancer Genet Cytogenet 1997 95: 210–212
Fontasch C, Haase D, Freund M, Bartels H, Tesch H . Partial trisomy 1q A nonrandom primary chromosomal abnormality in myelodysplastic syndromes? Cancer Genet Cytogenet 1991 56: 243–253
Verhoef G, Meeus P, Stul M, Mecucci C, Caissiman JJ, van den Berghe H, Boogaerts M . Cytogenetic and molecular studies of the Philadelphia translocation in myelodysplastic syndromes. Report of two cases and review of the literature Cancer Genet Cytogenet 1992 59: 161–166
Chen Z, Morgan R, Notohamiprodjo M, Meloni-Ehrig A, Schuster RT, Bennett JS, Cohen JD, Stone JF, Sandberg AA . The Philadelphia chromosome as a secondary change in leukemia: three case reports and an overview of the literature Cancer Genet Cytogenet 1998 101: 148–151
Katsuno M, Yamashita S, Sadamura S, Umemura T, Hirata J, Nishimura J, Nawata H . Late-appearing Philadelphia chromosome in a patient with acute non-lymphocytic leukemia derived from myelodysplastic syndrome: detection of P210- and P190-type bcr/abl fusion gene transcripts at the leukaemic stage Br J Haematol 1994 87: 51–56
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Seiter, K., Feldman, E., Sreekantaiah, C. et al. Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy. Leukemia 15, 963–970 (2001). https://doi.org/10.1038/sj.leu.2402122
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402122
Keywords
This article is cited by
-
A case of treatment-related myelodysplastic syndrome spontaneously resolved by drug discontinuance
International Journal of Hematology (2010)